A novel retinoic acid analog, 4-amino-2-trifluoromethyl-phenyl retinate, inhibits gastric cancer cell growth

Hu,Kong-Wang; Pan,Xiao-Hua; Chen,Fei-Hu; Qin,Rong; Wu,Li-Ming; Zhu,Hua-Gang; Wu,Fan-Rong; Ge,Jin-Fang; Han,Wen-Xiu; Yin,Chun-Lin; Li,Hong-Jun

doi:10.3892/ijmm.2013.1574

A novel retinoic acid analog, 4-amino-2-trifluoromethyl-phenyl retinate, inhibits gastric cancer cell growth

Authors:
- Kong-Wang Hu
- Xiao-Hua Pan
- Fei-Hu Chen
- Rong Qin
- Li-Ming Wu
- Hua-Gang Zhu
- Fan-Rong Wu
- Jin-Fang Ge
- Wen-Xiu Han
- Chun-Lin Yin
- Hong-Jun Li
View Affiliations

Affiliations: Department of General Surgery, The First Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Gynaecology and Obstetrics, The First Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, School of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Pathology, The First Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Radiotherapy, The First Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: December 4, 2013 https://doi.org/10.3892/ijmm.2013.1574
Pages: 415-422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoic acid (RA) analogs have been used in the treatment of a variety of cancers; however, their application is limited due to serious therapy-related sequelae. In the present study, the effects of a novel RA analog, 4-amino-2-trifluoromethyl-phenyl retinate (ATPR), on the growth of gastric cancer cells were evaluated. Three gastric cancer cell lines, AGS, MKN-74 and SC-M1, were treated with either all‑trans retinoic acid (ATRA) or ATPR, and their growth and distribution in different cell cycle phases were assessed using an MTT assay and propidium iodide (PI) staining followed by flow cytometry. The binding affinity of ATPR to the retinoic acid receptors, retinoic acid receptor-α (RAR-α) and retinoid X receptor-α (RXR-α), was determined using ligand-binding assays. Activator protein-1 (AP-1) activity was measured using a luciferase reporter assay. Western blot analysis was used to determine cyclin E, Bcl-2 and Bax protein expression. ATPR preferentially bound RXR-α (0.04 nM) as compared with RAR-α (20.96 nM). Although both ATRA and ATPR inhibited the growth of AGS, MKN-74 and SC-M1 cells in a dose-dependent manner, a significantly greater inhibitory effect was observed with treatment with 5 and 500 µM ATPR for 3 days (P<0.05). In addition, ATPR (50 µM), but not ATRA, significantly increased the population of AGS and MKN-74 cells in the subG1 phase and decreased the Bcl-2/Bax ratio (P<0.05). Furthermore, in MNK-74 and SC-M1 cells treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) and 5 or 10 µM of ATPR significantly suppressed the activity of the AP-1 reporter as compared to treatment with ATRA (P<0.05). Thus, ATPR inhibits cancer cell proliferation to a greater extent compared to ATRA, possibly through the RXR-mediated inhibition of AP-1 activity.

View Figures

View References

1	Campo-Paysaa F, Marlétaz F, Laudet V and Schubert M: Retinoic acid signaling in development: tissue-specific functions and evolutionary origins. Genesis. 46:640–656. 2008. View Article : Google Scholar : PubMed/NCBI
2	Mark M, Ghyselinck NB and Chambon P: Function of retinoic acid receptors during embryonic development. Nucl Recept Signal. 7:e0022009.PubMed/NCBI
3	McKenna NJ and O’Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 108:465–474. 2002. View Article : Google Scholar : PubMed/NCBI
4	Li JJ, Dong Z, Dawson MI and Colburn NH: Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 56:483–489. 1996.PubMed/NCBI
5	Liu S, Wu Q, Chen ZM and Su WJ: The effect pathway of retinoic acid through regulation of retinoic acid receptor alpha in gastric cancer cells. World J Gastroenterol. 7:662–666. 2001.PubMed/NCBI
6	Sundqvist A, Zieba A, Vasilaki E, Herrera Hidalgo C, Söderberg O, Koinuma D, Miyazono K, Heldin CH, Landegren U, Ten Dijke P and van Dam H: Specific interactions between Smad proteins and AP-1 components determine TGFβ-induced breast cancer cell invasion. Oncogene. 32:3606–3615. 2013.PubMed/NCBI
7	McKenna NJ: EMBO Retinoids 2011: Mechanisms, biology and pathology of signaling by retinoic acid and retinoic acid receptors. Nucl Recept Signal. 10:e0032012.PubMed/NCBI
8	Kilewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM: Covergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 358:771–774. 1992. View Article : Google Scholar : PubMed/NCBI
9	Dierov J, Sawaya BE, Prosniak M and Gartenhaus RB: Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res. 5:2540–2547. 1999.PubMed/NCBI
10	Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL and Benbrook DM: Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecol Oncol. 97:142–150. 2005. View Article : Google Scholar : PubMed/NCBI
11	Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M and Juliusson G: Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 25:1128–1134. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, Vourtsi A, Antoniades M, Gkirkas K, Tzouvara E, Katis F, Prokopiou C, Tziotziou I, Balta A, Lemissiou E, Tsirigotis P, Repoussis P and Harhalakis N: Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic acid era. Mediterr J Hematol Infect Dis. 3:e20110532011. View Article : Google Scholar : PubMed/NCBI
13	Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM and Tallman MS: Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 118:1248–1254. 2011. View Article : Google Scholar : PubMed/NCBI
14	Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M, Brunetti GA, Avvisati G, Lo Coco F and Mandelli F: Therapy-related myelodysplastic syndrome-acute myelogenous leukaemia in patients treated for acute promyelocytic leukaemia: an emerging problem. Blood. 99:822–824. 2002. View Article : Google Scholar
15	Zompi S and Viguie F: Therapy-related acute myeloid leukaemia and myelodysplasia after successful treatment of acute promyelocytic leukaemia. Leuk Lymphoma. 43:275–280. 2002. View Article : Google Scholar : PubMed/NCBI
16	Simoni D, Rondanin R, Baruchello R, Roberti M, Rossi M, Grimaudo S, D’Alessandro N, Invidiata FP and Tolomeo M: Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology. Pure Appl Chem. 73:1437–1444. 2001. View Article : Google Scholar
17	Adamson PC: All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist. 1:305–314. 1996.PubMed/NCBI
18	Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P and Levin AA: Retinoic acid receptors and retinoid X receptors interactions with endogenous retinoic acids. Proc Natl Acad Sci USA. 90:30–34. 1993. View Article : Google Scholar : PubMed/NCBI
19	Tang J, Yao J, Shi J, Xiao Q, Zhou J and Chen F: Synthesis, characterization, drug-loading capacity and safety of novel pH-independent amphiphilic amino acid copolymer micelles. Pharmazie. 67:756–764. 2012.PubMed/NCBI
20	Ahn HK, Jang J, Lee J, Se Hoon P, Park JO, Park YS, Lim HY, Kim KM and Kang WK: P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl Oncol. 4:345–349. 2011. View Article : Google Scholar : PubMed/NCBI
21	Li CJ, Chu CY, Huang LH, Wang MH, Sheu LF, Yeh JI and Hsu HY: Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 319:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, Chen DL, Ueno H, Chao W, Morikawa M, Ikeda Y, Heber D, Pfahl M and Koeffler HP: Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood. 87:1977–1984. 1996.PubMed/NCBI
23	Zang C, Wächter M, Liu H, Posch MG, Fenner MH, Stadelmann C, von Deimling A, Possinger K, Black KL, Koeffler HP and Elstner E: Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol. 65:107–118. 2003. View Article : Google Scholar : PubMed/NCBI
24	Wang N, Ge JF, Pan CX, Peng XQ, Chen HH, Wang XQ, Tang J, Hu W and Chen FH: Anti-tumor effect of 4-Amino-2-Trifluoromethyl-Phenyl Retinate on human breast cancer MCF-7 cells via up-regulation of retinoid receptor-induced gene-1. Biomed Pharmacother. 67:687–692. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wu Q, Chen YQ, Chen ZM, Chen F and Su WJ: Effects of retinoic acid on metastasis and its related proteins in gastric cancer cells in vivo and in vitro. Acta Pharmacol Sin. 23:835–841. 2002.PubMed/NCBI
26	Zhang JP, Chen XY and Li JS: Effects of all-trans-retinoic on human gastric cancer cells BGC-823. J Dig Dis. 8:29–34. 2007. View Article : Google Scholar : PubMed/NCBI
27	Agadir A, Shealy YF, Hill DL and Zhang X: Retinyl methyl ether down-regulates activator protein 1 transcriptional activation in breast cancer cells. Cancer Res. 57:3444–3450. 1997.PubMed/NCBI
28	Wan H, Dawson MI, Hong WK and Lotan R: Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: dependence on AP-1 activation, but not on retinoid response element activation. Oncogene. 15:2109–2118. 1997. View Article : Google Scholar : PubMed/NCBI
29	Wu Q, Chen ZM and Su WJ: Anticancer effect of retinoic acid via AP-1 activity repression is mediated by retinoic acid receptor alpha and beta in gastric cancer cells. Int J Biochem Cell Biol. 34:1102–1114. 2002. View Article : Google Scholar : PubMed/NCBI
30	Cory S and Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 8:5–6. 2005. View Article : Google Scholar : PubMed/NCBI
31	Reed JC: Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differen. 13:1378–1386. 2006. View Article : Google Scholar : PubMed/NCBI
32	Tacar O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2013. View Article : Google Scholar : PubMed/NCBI
33	Albano F, Arcucci A, Granato G, Romano S, Montagnani S, De Vendittis E and Ruocco MR: Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines. Biochimie. 95:934–945. 2013. View Article : Google Scholar : PubMed/NCBI
34	Mazumder S, Plesca D and Almasan A: A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation. Cell Cycle. 6:1437–1442. 2007. View Article : Google Scholar : PubMed/NCBI
35	López-Carballo G, Moreno L, Masiá S, Pérez P and Barettino D: Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem. 277:25297–25304. 2002.